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Investigating the family tree of a tumor to identify its cellular origins is a daunting task. Liu et al.
(2011) now use an elegant lineage tracing technique (MADM) to visualize glioma from its earliest
stages. They show thatmutations originally induced in neural stem cells lie dormant and only trigger
malignant transformation following differentiation into oligodendrocyte precursor cells.By the time a tumor has grown large
enough to be detected, it is often too
late to establish with any certainty how it
came to be there. Although cancer geno-
mics is providing impressive insights into
the mutations that drive cancer progres-
sion, it is not yet possible to use this infor-
mation to ‘‘rewind’’ tumor development
and establish exactly how (which muta-
tion) and where (in what cell type) the first
steps toward cancer occurred. In this
issue of Cell, Liu et al. take the reverse
approach, using a transgenic cell-labeling
system known as mosaic analysis with
double markers (MADM) to track tumor
growth in an inducible mouse glioma
model (Liu et al., 2011). Their results high-
light the subtle but important distinction
between where a mutation occurs (cell
of mutation) and where it drives tumor
development (cell of origin).
Glioma is the most common form of
primary brain tumor and includes
morphologically distinct cancers such as
astrocytoma, ependymoma, and oligo-
dendroglioma. This heterogeneity has
led many to suggest that driving muta-
tions might occur in the respective differ-
entiated cell types. In support of this
possibility, genetically engineered mouse
models have been used to demonstrate
that platelet-derived growth factor (Pdgf)
overexpression in conventionally non-
neurogenic niches results in glioma
formation (Hambardzumyan et al., 2009).
In addition, Pdgf overexpression in com-
mitted progenitors, such as oligodendro-
cyte precursor cells (OPCs), also initiates
tumors (Lindberg et al., 2009). These
results are further supported with datademonstrating that astrocytomas can
develop outside of proliferative niches
when mutations in Pten, p53, and Rb
pathways are combined, as well as
another study showing that activation of
wild-type and/or mutant Egfr combined
with ablation of tumor suppressor gene
function in the adult mouse striatum
results in glioma formation (Chow et al.,
2011, Zhu et al., 2009).
An alternative but not mutually exclu-
sive possibility for the origin of cancer
is that a mutated tissue stem cell could
directly give rise to distinct tumor line-
ages depending on the nature of the
affected signaling pathway (Visvader,
2011). Neural stem cells (NSCs) are likely
candidates for the cell of origin of glioma
due to their long lifetime, self-renewal,
and sustained proliferative capacity, as
well as commonalities with cancer stem
cells, which are defined by their ability
to propagate complex tumors when im-
planted into a host (Singh et al., 2004).
In support of this hypothesis, introduc-
tion of mutations associated with human
brain tumors into NSCs generates murine
gliomas in anatomical locations consis-
tent with a stem cell origin, such as the
subventricular zone (Alcantara Llaguno
et al., 2009; Wang et al., 2009; Zhu
et al., 2005).
Liu et al. address this debate by
tracing the growth of individual lineages
descended from a mutated NSC (Liu
et al., 2011). In their system, Cre-medi-
ated recombination in dividing NSCs
inactivates both p53 and Nf1 tumor
suppressors while simultaneously acti-
vating the expression of a green fluores-Cellcent protein (GFP) tracer. Alternative
recombination results in wild-type p53
and Nf1 but activates expression of red
fluorescent protein (RFP); nonrecom-
bined cells remain heterozygous null for
both genes and lack a fluorescent label
(Figure 1A). As such, Liu et al. discrimi-
nate between cells with oncogenic muta-
tions (green) and normal counterparts
(red) over time. Both wild-type and
mutant NSCs give rise to the expected
repertoire of neuronal and glial cell types.
However, only mutant NSCs give rise to
hyperproliferative oligodendrocyte pre-
cursor cells (OPCs) that eventually
develop into malignancies with varied
histological features. All other NSC-
derived cell types, including NSCs them-
selves, remain mostly unaffected by
disruption of the two tumor suppressive
pathways. Finally, when p53/Nf1 inacti-
vation is targeted specifically to OPCs,
tumors form that are essentially identical
to NSC-derived gliomas (Figure 1B).
Interestingly, these tumors acquired the
expression of NSC genes, which could
be misleading were it not for the earlier
analysis of cell lineages.
The findings demonstrate that, in p53/
Nf1 mutation-driven glioma, mutation
may initially occur in either NSCs or
OPCs, but only OPCs provide the suitable
cellular context needed for transforma-
tion. The importance of cellular context
in determining the outcome of a mutation
is also illustrated by inherited cancer
syndromes in which individuals harbor
oncogenic mutations in every cell but
develop tumors in only a small number
of tissues (such as BRCA1 mutations in146, July 22, 2011 ª2011 Elsevier Inc. 187
Figure 1. MADM Identifies Cell of Origin in Glioma
(A) The hierarchy of NSC differentiation. MADM recombination in dividing
NSCs resulting in p53/Nf1 inactivation also labels mutant cells with GFP. RFP-
labeled cells undergo alternative recombination to become wild-type for p53
and Nf1. Despite a shared genetic background in all mutant NSC-derived
lineages, only OPCs expand and give rise to glioma.
(B) Gliomagenesis also occurs when p53/Nf1 inactivation is targeted specifi-
cally to OPCs. These experiments also demonstrate that the cell of mutation
may or may not be distinct from the cell of origin in glioma.
NSC, neural stem cell; NB, neuroblast; OPC, oligodendrocyte precursor cell;
Astro, astrocyte.breast cancer). Though many
cancer types share common
genetic lesions, there is often
an association of specific
genetic changes with re-
stricted cancer types (for
example, theBCR-ABL fusion
in chronic myelogenous leu-
kemia). By highlighting the
role of differentiation state in
determining the outcome of
a particular mutation, Liu
et al. reconcile the debated
potential of both stem cells
and lineage-committed pre-
cursors as cellular targets in
cancer initiation.
It is not yet clear to what
extent the lineage specificity
of p53/Nf1 mutations is con-
served between mouse and
man. For example, com-
parative oncogenomics of
the mouse model tumors
matches them with human
proneural glioblastomas,
which are associated with
aberrant PDGFR signaling. In
contrast, NF1 mutations in
human glioblastomas typi-
cally correlate with the
mesenchymal subtype (Phil-
lips et al., 2006). This caveat
withstanding, the work will
undoubtedly focus attention
on OPCs as targets for glioma
investigators, devising new
means to halt cancer progres-
sion, especially for treatment-
refractory tumors. We should
also be open to the possibility
that distinct glioma subtypes
may be driven by different
cells of origin, and future
studies taking advantage of
MADM will be required to
determine whether OPCs are
also the cell of origin ingliomas with different driving mutations,
genetic backgrounds, and age at the
time of mutation. Finally, this powerful188 Cell 146, July 22, 2011 ª2011 Elsevier Intechnique will likely be applied to other
tumor types and could provide
a useful tool not only to identify cell ofc.origin, but also to rigorously
evaluate new methods for
detecting the earliest stages
of cancer.
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